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Bonn, GermanyA 77-year old woman presented with sudden onset
of dyspnea New York Heart Association func-
tional class IV, bilateral pleural effusion, and acuteFigure 1. Echocardiography, Angiography, and Hemodynamics Before
Treatment of Severe AR Due to Prosthesis Degeneration Following T
The patient presented with severe aortic regurgitation (AR) due to prolapse
indicated by a signiﬁcant backﬂow of contrast dye into the left ventricle d
line¼ pressure in the aorta; blue line¼ pressure in the left ventricle) See O
transesophageal echocardiography (TEE) (D) and aortography (E) conﬁrmed
paravalvular AR. See Online Videos 4, 5, and 6. The hemodynamic AR inde
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e72CoreValve 29-mm prosthesis (Medtronic, Minneapolis,
Minnesota).
Five months ago, routine follow-up after TAVR had been
uneventful with only trace paravalvular aortic regurgitation
(AR). Echocardiography revealed the new onset of severe
degenerative transvalvular AR with holodiastolic ﬂow
reversal in the aorta due to prolapse of 1 bioprosthetic valve
cusp, however, without signs of underlying prosthetic valve
endocarditis (Figs. 1A and 1B, Online Videos 1, 2, and 3).
The patient’s medical history was free of fever or other signs
of systemic inﬂammation (white blood cell count 7.88 g/l;
C-reactive protein 15.1 mg/l; procalcitonin 0.08 mg/l). Serial
blood cultures were without evidence for bacteremia.
Due to a Society of Thoracic Surgeons score of 9.6%
and previous TAVR in 2010, the Heart Team decided
to perform transcatheter heart valve (THV)-in-THV im-
plantation. The new prosthesis was successfully implanted at
the same height as the previous valve without pre-dilation.
Transesophageal echocardiography conﬁrmed competent
aortic valve leaﬂet coaptation without trans- or paravalvular
AR (Figs. 1D and 1E, Online Videos 4, 5, and 6). The
hemodynamic AR index increased signiﬁcantly from 18.8 to
34.6 (Figs. 1C and 1F) (1). After the procedure, the patient
improved immediately to New York Heart Association
functional class II (N-terminal pro–B-type natriuretic
peptide decreased from 5,435 pg/ml to 970 pg/ml) and
renal function restored to baseline values (serum creatinine
1.4 mg/dl).
Here, we report the ﬁrst case of a late-onset degenerative
transvalvular AR in a patient with the self-expandingMedtronic CoreValve bioprosthesis, which was treated
successfully by THV-in-THV implantation as an easily
feasible treatment strategy for long-term THV failure.
Furthermore, the order of events demonstrates the detri-
mental effect of severe AR on renal function culmi-
nating in cardio-renal syndrome, which appears to be
potentially reversible after restoration of valve and heart
function (1,2).
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APPENDIX
For supplemental videos, please see the online version of this article.
